1 Adult Health II Neurological Diseases Jerry Carley RN, MSN, MA, CNE Summer, 2010.

Slides:



Advertisements
Similar presentations
MOTOR NEURON DISEASE The motor neuron diseases (or motor neuron diseases) (MND) are a group of neurological disorders that selectively affect motor neurons.
Advertisements

Amyotropic Lateral Sclerosis (ALS)
Parkinson’s disease Dartington 26 June 2003
Linda Pituch, Patient Services Manager, Parkinson’s Disease Foundation
Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
An Overview of Conventional and Experimental Treatments
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Initial Diagnosis and Management of Parkinson’s Disease
Is it a neurodegenerative brain disorder that progresses slowly in most people.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Deep Brain Stimulation For parkinson’s disease
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
Parkinson’s Disease Busra Berika Yucel
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Parkinson’s Disease By Devin Cornford
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
BY: MACKENZIE SOARES ALYSSA MEDIEROS STEPHANIE GARDNER Parkinson's Disease.
Drugs For Parkinson's Disease. History of Parkinson's Disease l First characterized in 1817 by James Parkinson : An Essay On The Shaking Palsy.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Drugs used in Parkinson disease. Epidemiology Average age of onset 62.5 Men and women affected equally Genetic Link African-Americans and Asians less.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Benjamin L. Walter M.D. Medical Director, Deep Brain Stimulation Program Neurological Institute University Hospitals Case Medical Center Management of.
Guillain-Barre’ Syndrome
Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.
Parkinson’s Disease Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
Neurological Disorders
second most common neurodegenerative disorder progressive loss of muscle control trembling of the limbs and head while at rest stiffness, slowness, and.
Drugs in parkinsonism ilos
The Substantia Nigra THE BRAIN Symptoms differ from every person suffering from the disease. There are two types of symptoms, primary, secondary.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
CNS -Antiparkinsonian Drugs Discuss the signs and symptoms exhibited by a patient with Parkinson’s Disease Describe the actions and intended effects of.
Parkinson’s Test Device Development Tiffany Feltman Erin Sikkel.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pharmacological Treatment of Parkinson Disease: A.
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
PARKINSON’S DISEASE LUKE CARROLL & LAUREN DESROCHES.
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Drugs of Anti-Parkinson’s disease
Drugs for Parkinson’s Disease
Parkinson's disease KRZYSZTOF NICPOŃ.
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Anti-parkinsonism Drugs
WHAT I NEED TO KNOW AS A PATIENT AND A CAREGIVER
Anti-parkinsonism Drugs
Drugs for Degenerative Diseases of the Nervous System
Classification of Epilepsy (p. 227)
Neurodegenerative diseases
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

1 Adult Health II Neurological Diseases Jerry Carley RN, MSN, MA, CNE Summer, 2010

Concept Map: Selected Topics in Neurological Nursing PATHOPHYSIOLOGY Traumatic Brain Injury Spinal Cord Injury Specific Disease Entities: Amyotropic Lateral Sclerosis Multiple Sclerosis Huntington’s Disease Alzheimer’s Disease Huntington’s Disease Myasthenia Gravis Guillian-Barre’ Syndrome Meningitis Parkinson’s Disease PHARMACOLOGY --Decrease ICP --Disease / Condition Specific Meds ASSESSMENT Physical Assessment Inspection Palpation Percussion Auscultation ICP Monitoring “Neuro Checks” Lab Monitoring Diagnostic Testing Care Planning Plan for client adl’s, Monitoring, med admin., Patient education, more…based On Nursing Process: A_D O_P_I_E Nursing Interventions & Evaluation Execute the care plan, evaluate for Efficacy, revise as necessary A-D-O-P-I-E

 Progressive  Grossly affects motor function  Symptoms of Parkinson's disease may appear at any age, but the average age of onset is 60  Rare in people younger than 30, but 5% - 10% of pts experience symptoms before the age of 40 3

 Normally Dopamine & Ach neurotransmitters work together to enable motor neurons to refine voluntary movement  Parkinson's results from the degeneration of dopamine-producing nerve cells in the brain, specifically in the substantia nigra and locus coeruleus  Clients have lost 80% or more of their dopamine-producing cells by the time symptoms appear 4

5

6

7

1)Tremors (at rest) 2)Muscle Rigidity (may produce muscle pain, expressionless, mask-like face, difficulty chewing) 3)Bradykinesia (slow movement) 4)Cognitive impairment (mood swings…dementia) 5)Postural instability: - Falls are common - Poor balance - Stooped posture - Difficulty walking (slow, shuffling, propulsive gait) 8

 Based on symptoms and ruling out other disorders that produce similar symptoms  Must have two or more of the primary symptoms, one of which is a resting tremor or bradykinesia  Often diagnosis is made after observing that symptoms have developed and become established over a period of time 9

 There is no cure for Parkinson's disease  Treatment centers on relieving symptoms  meds  surgery or surgically implanted device that lessens tremors 10

Dopamine Replacement / Agonists  Levodopa (DOPAR) - can become ineffective over time - abnormal movements (dyskinesias)  Levodopa and carbidopa combined (Sinemet®) is the mainstay of Parkinson's therapy  Side effects: gastrointestinal distress, especially early in treatment, hypotension, and dyskinesias  Slow dosage adjustment and taking medication with food can reduce these effects and using lowest effective dose may prevent or delay appearance of motor dysfunction 11

Dopamine Agonists  Parlodel  Mirapex (pramipexole)  Side effects: hypotension and hallucinations 12

13  Dopamine Agonists Dopamine agonists mimic dopamine's function in the brain. They are used primarily as adjuncts to levodopa/carbidopa therapy. They can be used as monotherapy but are generally less effective in controlling symptoms with Side effects similar to those produced by levodopa - Bromocriptine (Parlodel®) - Pergolide (Permax®) - Pramipexole (Mirapex®) - Ropinirole (Requip®)  MAO-B Inhibitors Dopamine is oxidized by monoamine oxidase B (MAO-B). Selegiline (Carbex®) inhibits MAO-B, increasing the amount of available dopamine in the brain. MAO-B inhibitors boost the effects of levodopa  Anticholinergics reduce the relative overactivity of the neurotransmitter acetylcholine to balance the diminished dopamine activity. This class of drugs is most effective in the control of tremor, and they are used as adjuncts to levodopa. Side effects associated with anticholinergic drugs include dry mouth, blurred vision, constipation, and urinary retention - Benztropine mesylate (Cogentine®) - Biperiden (Akineton®) - Diphenhydramine (Benadryl®) - Trihyxyphenidyl (Artane®)  COMT (catechol-O-methyl transferase) Inhibitors These new class of Parkinson's medications augment levodopa therapy by inhibiting the COMT enzyme, which metabolizes levodopa before it reaches the brain. Inhibiting COMT increases the amount of levodopa that enters the brain. These drugs are only effective when used with levodopa - Entacapone (Comtan®) - Tolcapone (Tasmar®)

 It is imperative that patients inform their physician of any over-the-counter medications, herbs, or other supplements that they use on a regular basis, because they may interact with medication and because drug dosages may need to be adjusted 14

 Surgery may control symptoms and improve quality of life when medication ceases to be effective or when medication side effects, such as jerking and dyskinesias, become intolerable  Only about 10% of Parkinson's patients are estimated to be suitable candidates 15

16 Ablative Surgery - This procedure locates, targets, and then destroys (ablates) a clearly defined area of the brain affected by Parkinson's - The object is to destroy tissue that produces abnormal chemical or electrical impulses that produce tremors and dyskinesias - This type of surgery involves either pallidotomy or thalamotomy - A related procedure, cryothalamotomy, uses a supercooled probe that is inserted into the thalamus to freeze and destroy areas that produce tremors Deep Brain Stimulation (DBS) - DBS targets the subthalamic nucleus, which is located below the thalamus and is difficult to reach, the globus pallidus, or the thalamus - Targeted region is inactivated, not destroyed, by an implanted electrode Transplantation or Restorative Surgery - In transplantation, or restorative, surgery dopamine-producing cells are implanted into the striatum - The cells used for transplantation may come from one of several sources: the patient's body, human embryos, pig embryos

 Goal = help relieve symptoms & improve quality of life  Physical therapy can help strengthen and tone underused muscles, and give rigid muscles a better range of motion. The goal is to help build body strength, improve balance, overcome gait problems, and improve speaking and swallowing  Simple physical activity such as walking, gardening, and swimming can improves one's sense of well-being  Gentle, soothing massage techniques may provide relief from muscle rigidity and may have some neuromuscular benefit as well  The slow flowing movements of Tai Chi help maintain flexibility, balance, and relaxation  Support groups provide a caring supportive environment in which patients and their loved ones can ask questions about Parkinson's, expressing their frustrations, and obtain advice about coping with and treating symptoms from people who share the same problem  Parkinson's appears to progress more slowly in those who remain involved in activities that they enjoyed before the onset of symptoms and in those who engage in new interests 17